TrialA Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
Trial details
- Registry ID
- NCT04049266
- Phase
- Phase 2, Phase 3
KOD
Kodiak Sciences Inc
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
10Trials in this database
10Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceA Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
Trial details
- Registry ID
- NCT04592419
- Phase
- Phase 3
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
Trial details
- Registry ID
- NCT04603937
- Phase
- Phase 3
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
Trial details
- Registry ID
- NCT04611152
- Phase
- Phase 3
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Trial details
- Registry ID
- NCT04964089
- Phase
- Phase 3
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
Trial details
- Registry ID
- NCT05066230
- Phase
- Phase 3
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
Trial details
- Registry ID
- NCT06270836
- Phase
- Phase 3
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
Trial details
- Registry ID
- NCT06556368
- Phase
- Phase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
Trial details
- Registry ID
- NCT06990399
- Phase
- Phase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
Trial details
- Registry ID
- NCT06996080
- Phase
- Phase 3
Latest recorded trial changes
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
NCT06996080 · Kodiak Sciences Inc
Planned enrollment increased by 150 participants
− Before
150 participants (planned)
+ After
300 participants (planned)
Primary completion date changed
− Before
Dec 2026
+ After
Feb 2027
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
NCT06990399 · Kodiak Sciences Inc
Planned enrollment increased by 450 participants
− Before
150 participants (planned)
+ After
600 participants (planned)
Primary completion date changed
− Before
Feb 2026
+ After
Apr 2027
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
NCT06270836 · Kodiak Sciences Inc
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
31 Jan 2026
+ After
13 Feb 2026
Recruitment status changed
− Before
Active not recruiting
+ After
Completed
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT06556368 · Kodiak Sciences Inc
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Best corrected visual acuity (PCVA
+ After
Measure: Best corrected visual acuity (BCVA)
Primary completion date changed
− Before
Apr 2026
+ After
Aug 2026
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting